Pfizer Asks For Biden’s Co-operation To Incentivize Biosimilar Uptake

As Company’s Biosimilars Turnover Grows By Over 80% In Q1

Pfizer is looking for the Biden administration’s co-operation to address the policy issue of affordability and access to biosimilars. In the first quarter, the company’s biosimilars segment grew by 84% on the back of new launches, especially in the US where biosimilars sales nearly doubled. 

US_Pfizer
Pfizer says it is working with the Biden administration for solutions for patient access • Source: Alamy

Pfizer Inc. says it wants to actively engage in addressing the policy issue of affordable access, with the company looking to work with US president Joe Biden’s administration on finding “meaningful solutions” for patient access through incentivizing the uptake of biosimilars, as well as through rebate reform and capping beneficiary cost-sharing in Medicare Part D..

Albert Bourla, chairman and CEO of Pfizer commented, “We expect the Biden administration will soon announce a human capital component...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business